Additional support is derived from the study by Tarhini et al., who reported that elevated baseline levels of circulating IL-17 were significantly (P = 0.02) associated with the development of enterocolitis in ipilimumab-treated patients with advanced melanoma (38). The gene discussed is IL17A; the disease is melanoma.